22-Panel Drug Test
The 22-Panel Drug Test takes a significant step in expanding its testing list to include methamphetamines, lorazepam, and lorazepam metabolites. This test screens for marijuana (THC), cocaine, opiates, amphetamines, phencyclidine (PCP), benzodiazepines, barbiturates, methadone, propoxyphene, methaqualone, MDMA, oxycodone, tramadol, fentanyl, meperidine, ketamine, buprenorphine, kratom, synthetic cannabinoids, synthetic cathinones, methamphetamines, and lorazepam.
Expansive Screening for Comprehensive Detection
The 22-Panel Drug Test includes additional substances like methamphetamines, lorazepam, and synthetic cannabinoids, offering an even more comprehensive screening option for high-risk environments.
This test includes 22 substances, covering a wide array of both legal and illegal drugs, making it perfect for environments with extensive substance misuse concerns.
The 22-Panel Drug Test is useful for legal professionals, healthcare providers, and employers who require a broad and detailed understanding of an individual’s drug use.
This test is frequently used in rehabilitation centers to monitor a patient’s drug use during their recovery process, providing important information for treatment planning.
Like other tests in the panel series, the 22-Panel Drug Test delivers rapid, accurate results, allowing organizations to make informed decisions quickly about employee safety or legal matters.